CTRI/2024/06/068636尚未招募2 期
A Phase II Study of Cabozantinib in Metastatic/Unresectable Refractory Gastrointestinal Stromal Tumor - NI
I0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •a) Age 18-75 years
- •b) Gastro-Intestinal Stromal tumor confirmed histologically.
- •c) Metastatic/Unresectable disease, relapsed post 3 lines of therapy
- •d) ECOG Performance status (PS) =2
- •e) Absolute Neutrophil Count >1000/mcl, Hemoglobin >8.0g/dL,Platelet > 1,00,000/mcL
- •f) Normal renal function (Normal spot urine, Creatinine <1.5xULN, and eGFR >30ml/min)
- •g) Total bilirubin < 2.5x institutional ULN, ALT and AST <2.5 x ULN, alkaline phosphatase <2.5 x
排除标准
- •a) Pregnant or breastfeeding patient
- •b) Active or uncontrolled infection
- •c) Locally recurrent disease, which is amenable to curative surgical resection.
- •d) History of cardiac disease
- •e) Uncontrolled hypertension and arterial or venous thrombotic disease
- •f) Prior treatment with cabozantinib
研究者
相似试验
进行中（未招募）
2 期
Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal CancerColorectal AdenocarcinomaColon AdenocarcinomaRectum CancerRectal CancerRectal AdenocarcinomaColorectal CancerColon CancerNCT04963283University of Colorado, Denver48
招募中
1 期
A phase II trial of Cabozantinib medication in patients with advanced, high-grade neuroendocrine neoplasms, which are either well-differentiated neuroendocrine tumors or poor-differentiated neuroendocrine carcinoma but with a low proliferation rate. Both neuroendocrine neoplasms are insensitive against the available chemotherapy choice, making the newly investigated medication a new hope for better management of these subtypes.We will include patients with NET G3 in upto four different antitumoral therapies and NEC Ki67 low after failure of standard treatment with conventional chemotherapy.EUCTR2020-002541-41-ATniversitätsmedizin Göttingen
进行中（未招募）
1 期
A phase II trial of Cabozantinib medication in patients with advanced, high-grade neuroendocrine neoplasms, which are either well-differentiated neuroendocrine tumors or poor-differentiated neuroendocrine carcinoma but with a low proliferation rate. Both neuroendocrine neoplasms are insensitive against the available chemotherapy choice, making the newly investigated medication a new hope for better management of these subtypes.We will include patients with NET G3 and upto four prior antitumoral treatment lines and NEC Ki67 low after failure of standard treatment with conventional chemotherapy.EUCTR2020-002541-41-DEniversitätsmedizin Göttingen
已完成
2 期
Cabozantinib for Adults With Advanced Soft Tissue SarcomaRefractory Soft Tissue SarcomasNCT01755195National Cancer Institute (NCI)55
进行中（未招募）
1 期
Cabozantinib treatment for patients with hepatocellular carcinoma (HCC) refractory to previous treatmentHepatocellular carcinomaEUCTR2019-004126-13-DEniversity Leipzig40